1 型糖尿病扩展研究 (T1DES)
This is a multi-center, prospective, non-interventional study that focuses on the long- term effects following participation in selected ITN new-onset Type1 Diabetes Mellitus studies with immunomodulatory agents (T1DM, T1D).
This observational study will:
- follow participants to determine how long they continue to produce insulin, and
- will also assess how changes in the immune system over time relate to the ability to produce insulin.
This information could help design better therapies for type 1 diabetes in the future.
研究概览
详细说明
Depending upon a participant's level of insulin production, participation may be as short as one return visit or a maximum of five years. Evaluation visits will include:
- Overall health assessments
- Blood and urine collections
- Mixed meal tolerance test (MMTTs) for certain participants, per protocol.
研究类型
注册 (估计的)
联系人和位置
学习地点
-
-
California
-
San Francisco、California、美国、94143
- 招聘中
- UCSF School of Medicine
-
接触:
- Rebecca Wesch
- 电话号码:415-476-5984
- 邮箱:rebecca.wesch@ucsf.edu
-
首席研究员:
- Stephen Gitelman, MD
-
Stanford、California、美国、94305
- 招聘中
- Stanford University
-
接触:
- Trudy Esrey
- 电话号码:650-498-4450
- 邮箱:tesrey@stanford.edu
-
首席研究员:
- Darrell Wilson, MD
-
-
Colorado
-
Aurora、Colorado、美国、80045
- 招聘中
- University of Colorado School of Medicine: Barbara Davis Center for Diabetes
-
首席研究员:
- Peter Gottlieb, MD
-
接触:
- Mara Kinney
- 电话号码:(303) 724-8272
- 邮箱:MARA.KINNEY@ucdenver.edu
-
-
Connecticut
-
New Haven、Connecticut、美国、06519
- 完全的
- Yale University
-
-
Georgia
-
Atlanta、Georgia、美国、30322
- 撤销
- Emory University
-
-
Indiana
-
Indianapolis、Indiana、美国、46202
- 招聘中
- Indiana University Riley Hospital for Children
-
接触:
- Ellie Ryan
- 电话号码:317-278-7037
- 邮箱:elmryan@iu.edu
-
接触:
- Maria Spall
- 电话号码:317-278-7034
- 邮箱:malnicho@iu.edu
-
首席研究员:
- Linda DiMeglio, MD, MPH
-
-
Iowa
-
Iowa City、Iowa、美国、52242
- 招聘中
- University of Iowa Health Care Division of Pediatric Endocrinology
-
接触:
- Joanne Cabbage
- 电话号码:319-356-4035
- 邮箱:joanne-cabbage@uiowa.edu
-
首席研究员:
- Michael Tansey, MD
-
-
Massachusetts
-
Boston、Massachusetts、美国、02215
- 招聘中
- Joslin Diabetes Center
-
接触:
- Site Public Contact
- 电话号码:888-813-8669
- 邮箱:T1DTrials@joslin.harvard.edu
-
首席研究员:
- Jason Gaglia, MD
-
-
Minnesota
-
Minneapolis、Minnesota、美国、55454
- 招聘中
- University of Minnesota
-
接触:
- Anne Street
- 电话号码:612-625-9709
- 邮箱:stree065@umn.edu
-
首席研究员:
- Antoinette Moran, MD
-
-
Missouri
-
Kansas City、Missouri、美国、64108
- 完全的
- Children's Mercy Hospital
-
-
South Dakota
-
Sioux Falls、South Dakota、美国、57104
- 完全的
- Sanford Research
-
-
Washington
-
Seattle、Washington、美国、98101
- 招聘中
- Benaroya Research Institute
-
首席研究员:
- Sandra Lord, MD
-
接触:
- Katie Bennett
- 电话号码:(206) 341-8945
- 邮箱:kbennett@benaroyaresearch.org
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Former participants in Immune Tolerance Network (ITN) new-onset Type 1 Diabetes Mellitus (T1DM) studies with immunomodulatory agents as the intervention.
描述
Inclusion Criteria:
- Prior participant in an Immune Tolerance Network (ITN) executive committee approved T1DM study.
- Ability to sign informed consent/assent (as applicable for children).
Exclusion Criteria:
- Any medical condition that in the opinion of the principal investigator would interfere with safe completion of the trial; or
- Inability to comply with the study visit schedule and required assessments.
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
|---|
|
Group 1: Detectable C-peptide by MMTT
Participants with detectable C-peptide at their:
Detectable C-peptide is defined as a value above the lower limit of detection. |
|
Group 2:Undetectable C-peptide by MMTT
Participants without detectable C-peptide at their:
Undetectable C-peptide is defined as a value below the lower limit of detection. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Beta Cell Function by MMTT-Stimulated Mean C-peptide Area Under the Curve (AUC)
大体时间:Baseline (Visit 0) to Month 60 (Year 5)
|
Evaluation of changes in beta cell function over time will be measured by mixed-meal tolerance test (MMTT) -Stimulated mean C-Peptide area under the curve (AUC). C-peptide is released by the pancreas into the bloodstream in equal amounts to insulin and reflects how much insulin pancreatic beta cells are making. The standardized MMTT evaluates whether beta cells are producing endogenous insulin. Detectable C-peptide is defined as any value during a MMTT of ≥0.15 ng/mL. |
Baseline (Visit 0) to Month 60 (Year 5)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Insulin Use in Units per Kilogram Body Weight Per Day
大体时间:Baseline (Visit 0) to Month 60 (Year 5)
|
The need to use exogenous insulin is an indication that the body is not producing enough endogenous insulin. Higher amounts of insulin use indicate higher disease activity. |
Baseline (Visit 0) to Month 60 (Year 5)
|
|
Change in HbA1C
大体时间:Baseline (Visit 0) to Month 60 (Year 5)
|
Glycosylated hemoglobin (HbA1c) is a measure of the average plasma concentration of blood sugar (glucose) over the previous three months and measures the level of optimal management of underlying disease. |
Baseline (Visit 0) to Month 60 (Year 5)
|
|
Count of Participant-Reported Major Hypoglycemic Events
大体时间:Baseline (Visit 0) to Month 60 (Year 5)
|
Major hypoglycemic events are defined as a glucose concentration <55 mg/dL (grades 2-5, NCI-CTCAE version 4.03), or clinically: involving seizure(s) or involving loss of consciousness (coma), or requiring assistance from another individual in order to recover. |
Baseline (Visit 0) to Month 60 (Year 5)
|
|
Time to Undetectable C-Peptide
大体时间:Baseline (Visit 0) to Month 60 (Year 5)
|
To assess the longevity of beta cell function, time to undetectable C-peptide will be evaluated using Kaplan-Meier survival estimates. |
Baseline (Visit 0) to Month 60 (Year 5)
|
|
Frequency of Grade 3 or Higher Adverse Events (AEs) of Interest
大体时间:Baseline (Visit 0) to Month 60 (Year 5)
|
Events of interest include but are not limited to:
Reference for Grade 3 or higher AEs: National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.03 (June 14, 2010). |
Baseline (Visit 0) to Month 60 (Year 5)
|
|
Severity of Grade 3 or Higher Adverse Events (AEs) of Interest
大体时间:Baseline (Visit 0) to Month 60 (Year 5)
|
Events of interest include but are not limited to:
Reference for Grade 3 or higher AEs: National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.03 (June 14, 2010). |
Baseline (Visit 0) to Month 60 (Year 5)
|
合作者和调查者
调查人员
- 学习椅:Linda A. DiMeglio, MD, MPH,MA、Riley Hospital for Children at Indiana University Health
出版物和有用的链接
一般刊物
- Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J, Bluestone JA; AbATE Study Team. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes. 2013 Nov;62(11):3766-74. doi: 10.2337/db13-0345. Epub 2013 Jul 8.
- Rigby MR, Harris KM, Pinckney A, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Keyes-Elstein L, Long SA, Kanaparthi S, Lim N, Phippard D, Soppe CL, Fitzgibbon ML, McNamara J, Nepom GT, Ehlers MR. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest. 2015 Aug 3;125(8):3285-96. doi: 10.1172/JCI81722. Epub 2015 Jul 20.
- Rigby MR, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Patel CM, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Moran A, Russell WE, Pinckney A, Keyes-Elstein L, Howell M, Aggarwal S, Lim N, Phippard D, Nepom GT, McNamara J, Ehlers MR; T1DAL Study Team. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol. 2013 Dec;1(4):284-94. doi: 10.1016/S2213-8587(13)70111-6. Epub 2013 Sep 23.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- DAIT ITN066AI
- NIAID CRMS ID#: 20722 (其他标识符:DAIT NIAID)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
The plan is to share data in: 1.)ImmPort, a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts that also provides data analysis tools that are available to researchers who register online and subsequently receive DAIT approval; and 2.)TrialShare, a clinical trials research portal developed by the Immune Tolerance Network that makes data from the consortium's clinical trials publicly available without charge.
IPD 共享时间框架
After completion of the study.
IPD 共享访问标准
Will be available to the public.
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.